JP2006510627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510627A5 JP2006510627A5 JP2004556536A JP2004556536A JP2006510627A5 JP 2006510627 A5 JP2006510627 A5 JP 2006510627A5 JP 2004556536 A JP2004556536 A JP 2004556536A JP 2004556536 A JP2004556536 A JP 2004556536A JP 2006510627 A5 JP2006510627 A5 JP 2006510627A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- dihydroxy
- pyrazole
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 4
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- IXCXMVFSSFOBRS-UHFFFAOYSA-N 4-[[[5-(5-chloro-2,4-dihydroxyphenyl)-1H-pyrazole-4-carbonyl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O IXCXMVFSSFOBRS-UHFFFAOYSA-N 0.000 claims 1
- BNWSRRYLRSEHCW-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-[(4-chlorophenyl)methyl]-1H-pyrazole-4-carboxamide Chemical compound C1=C(Cl)C(O)=CC(O)=C1C1=NNC=C1C(=O)NCC1=CC=C(Cl)C=C1 BNWSRRYLRSEHCW-UHFFFAOYSA-N 0.000 claims 1
- MJEHKTOWJZRXHY-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-[(4-methylphenyl)methyl]-1H-pyrazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CNC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O MJEHKTOWJZRXHY-UHFFFAOYSA-N 0.000 claims 1
- GSTPJSTXWSHLQL-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-[(4-methylsulfonylphenyl)methyl]-1H-pyrazole-4-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CNC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O GSTPJSTXWSHLQL-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- YXTPBDGYLVOSFA-UHFFFAOYSA-N N-(4-carbamoylphenyl)-5-(5-chloro-2,4-dihydroxyphenyl)-1H-pyrazole-4-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1NC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O YXTPBDGYLVOSFA-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- DKSYLXZOIPJWAM-UHFFFAOYSA-N chembl200318 Chemical compound C1=C(Cl)C(O)=CC(O)=C1C1=NNC=C1C(=O)NC1=CC=CC=C1 DKSYLXZOIPJWAM-UHFFFAOYSA-N 0.000 claims 1
- RPOVUZUSJOJMKK-UHFFFAOYSA-N chembl200360 Chemical compound COC1=CC=CC(CNC(=O)C=2C(=NNC=2)C=2C(=CC(O)=C(Cl)C=2)O)=C1 RPOVUZUSJOJMKK-UHFFFAOYSA-N 0.000 claims 1
- IYRSFBCXSHAWJI-UHFFFAOYSA-N chembl200556 Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O IYRSFBCXSHAWJI-UHFFFAOYSA-N 0.000 claims 1
- KSQXYHCHSNPQNL-UHFFFAOYSA-N chembl200570 Chemical compound C1=C(Cl)C(O)=CC(O)=C1C1=NNC=C1C(=O)NCC1=CC=C(F)C=C1 KSQXYHCHSNPQNL-UHFFFAOYSA-N 0.000 claims 1
- HTVWCFLLANRGAP-UHFFFAOYSA-N chembl200654 Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O HTVWCFLLANRGAP-UHFFFAOYSA-N 0.000 claims 1
- ILQMLJRCOQFSII-UHFFFAOYSA-N chembl370769 Chemical compound C1=CC(NC(=O)C)=CC=C1NC(=O)C1=CNN=C1C1=CC(Cl)=C(O)C=C1O ILQMLJRCOQFSII-UHFFFAOYSA-N 0.000 claims 1
- UHTAKNSQMNRCJA-UHFFFAOYSA-N chembl371963 Chemical compound C1=C(Cl)C(O)=CC(O)=C1C1=NNC=C1C(=O)NC1=CC=C(Cl)C=C1 UHTAKNSQMNRCJA-UHFFFAOYSA-N 0.000 claims 1
- MCELZAVXRGEPDE-UHFFFAOYSA-N chembl382083 Chemical compound C1=C(Cl)C(O)=CC(O)=C1C1=NNC=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 MCELZAVXRGEPDE-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- BTTFXKUTBNGQTP-UHFFFAOYSA-N n-(4-acetylphenyl)-5-(5-chloro-2,4-dihydroxyphenyl)-1h-pyrazole-4-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=C(C=2C(=CC(O)=C(Cl)C=2)O)NN=C1 BTTFXKUTBNGQTP-UHFFFAOYSA-N 0.000 claims 1
- OOHYJGNSESWEFT-UHFFFAOYSA-N n-[4-(aminosulfonyl)benzyl]-5-(5-chloro-2,4-dihydroxyphenyl)-1h-pyrazole-4-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(=O)C1=C(C=2C(=CC(O)=C(Cl)C=2)O)NN=C1 OOHYJGNSESWEFT-UHFFFAOYSA-N 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0228417.2A GB0228417D0 (en) | 2002-12-05 | 2002-12-05 | Pyrazole compounds |
| PCT/GB2003/005275 WO2004050087A1 (en) | 2002-12-05 | 2003-12-04 | 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006510627A JP2006510627A (ja) | 2006-03-30 |
| JP2006510627A5 true JP2006510627A5 (enExample) | 2007-01-25 |
| JP4575779B2 JP4575779B2 (ja) | 2010-11-04 |
Family
ID=9949145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004556536A Expired - Fee Related JP4575779B2 (ja) | 2002-12-05 | 2003-12-04 | 癌治療用のｈｓｐ９０阻害剤としての３−（２−ヒドロキシ−フェニル）−１ｈ−ピラゾール−４−カルボン酸アミド誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7803831B2 (enExample) |
| EP (1) | EP1567151B1 (enExample) |
| JP (1) | JP4575779B2 (enExample) |
| CN (1) | CN1744894A (enExample) |
| AT (1) | ATE320252T1 (enExample) |
| AU (1) | AU2003285584A1 (enExample) |
| BR (1) | BR0316146A (enExample) |
| CA (1) | CA2508574A1 (enExample) |
| DE (1) | DE60304059T2 (enExample) |
| GB (1) | GB0228417D0 (enExample) |
| WO (1) | WO2004050087A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044586A1 (es) * | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
| WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| DE102004039280A1 (de) | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
| JP4820758B2 (ja) | 2004-09-22 | 2011-11-24 | 日本化薬株式会社 | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
| FR2876079A1 (fr) | 2004-10-06 | 2006-04-07 | Michel Gautier | Dispositif de largage d'un moyen de secours multi-actions, notamment un radeau de sauvetage |
| DE102004049078A1 (de) * | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| CN101072759B (zh) | 2004-11-18 | 2013-06-19 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
| DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| CN101160291B (zh) * | 2005-03-09 | 2012-09-05 | 日本化药株式会社 | 作为hsp90抑制剂的三唑衍生物 |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| PL1877379T3 (pl) * | 2005-04-13 | 2013-06-28 | Astex Therapeutics Ltd | Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90 |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2007021877A1 (en) | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
| KR20080106254A (ko) | 2006-03-28 | 2008-12-04 | 니폰 가야꾸 가부시끼가이샤 | 탁산류의 고분자 결합체 |
| RU2447095C2 (ru) | 2006-05-18 | 2012-04-10 | Ниппон Каяку Кабусики Кайся | Высокомолекулярный конъюгат подофиллотоксинов |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| CA2659155A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
| JP2009544626A (ja) * | 2006-07-21 | 2009-12-17 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｉｔｐｋｂ阻害剤としての化合物および組成物 |
| US20090239782A1 (en) | 2006-10-03 | 2009-09-24 | Masaharu Nakamura | High-molecular weight conjugate of resorcinol derivatives |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
| US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
| DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| CA2679126A1 (en) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | Macrocyclic compound |
| WO2008157210A1 (en) * | 2007-06-15 | 2008-12-24 | Irm Llc | Compounds and compositions as itpkb inhibitors |
| WO2009007399A1 (en) * | 2007-07-12 | 2009-01-15 | Crystax Pharmaceuticals, S.L. | New compounds as hsp90 inhibitors |
| WO2009041570A1 (ja) | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
| CA2700893A1 (en) | 2007-10-12 | 2009-04-16 | Arqule, Inc. | Substituted tetrazole compounds and uses thereof |
| CN101977631A (zh) | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
| LT5623B (lt) | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| WO2010048207A2 (en) * | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
| US8309578B2 (en) | 2008-11-25 | 2012-11-13 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2471918A4 (en) | 2009-09-29 | 2013-06-05 | Takeda Pharmaceutical | SCREENING METHOD |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
| WO2012103071A2 (en) * | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| KR101317656B1 (ko) * | 2011-06-30 | 2013-10-15 | 연세대학교 산학협력단 | 복제효소 인산화를 조절하는 신규 ｃ형 간염 예방 또는 치료용 조성물 |
| RU2623426C2 (ru) | 2011-09-11 | 2017-06-26 | Ниппон Каяку Кабусики Кайся | Способ получения блок-сополимера |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法 |
| AU2012339679A1 (en) | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
| CN103724269B (zh) * | 2012-10-11 | 2016-12-21 | 中国科学院上海药物研究所 | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 |
| EP3655393A1 (de) | 2017-07-18 | 2020-05-27 | Bayer CropScience Aktiengesellschaft | Substituierte 5-(het-)arylpyrazolamide sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| AU2019364352A1 (en) | 2018-10-22 | 2021-06-03 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| WO2000007996A2 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| EP1335920B1 (en) * | 2000-11-02 | 2013-04-03 | Sloan-Kettering Institute For Cancer Research | Compositions containing purine derivatives for binding to hsp90 |
| US7307097B2 (en) * | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
| US7247734B2 (en) * | 2001-12-21 | 2007-07-24 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
-
2002
- 2002-12-05 GB GBGB0228417.2A patent/GB0228417D0/en not_active Ceased
-
2003
- 2003-12-04 AT AT03778583T patent/ATE320252T1/de not_active IP Right Cessation
- 2003-12-04 DE DE60304059T patent/DE60304059T2/de not_active Expired - Lifetime
- 2003-12-04 EP EP03778583A patent/EP1567151B1/en not_active Expired - Lifetime
- 2003-12-04 WO PCT/GB2003/005275 patent/WO2004050087A1/en not_active Ceased
- 2003-12-04 US US10/536,898 patent/US7803831B2/en not_active Expired - Fee Related
- 2003-12-04 AU AU2003285584A patent/AU2003285584A1/en not_active Abandoned
- 2003-12-04 BR BR0316146-3A patent/BR0316146A/pt not_active IP Right Cessation
- 2003-12-04 JP JP2004556536A patent/JP4575779B2/ja not_active Expired - Fee Related
- 2003-12-04 CA CA002508574A patent/CA2508574A1/en not_active Abandoned
- 2003-12-04 CN CNA2003801095070A patent/CN1744894A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510627A5 (enExample) | ||
| JP6017313B2 (ja) | 化合物および方法 | |
| CN103121996B (zh) | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 | |
| JP5068768B2 (ja) | １１ベータ−ｈｓｄ１阻害剤としてのチアゾール | |
| JP2012510989A5 (enExample) | ||
| JP2016135778A (ja) | シアノトリアゾール化合物の医薬用途 | |
| JP2016525069A (ja) | シアノトリアゾール化合物 | |
| JP2004502768A (ja) | 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性 | |
| JP2013507355A (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| KR20060096995A (ko) | 중성구 엘라스타제 억제제로서의 2-피리돈 유도체 및 그의용도 | |
| WO2002102778A1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| JP2005509003A5 (enExample) | ||
| Vasudevan et al. | Heterocyclic ketones as inhibitors of histone deacetylase | |
| JP2009508949A5 (enExample) | ||
| JPWO2011043359A1 (ja) | 芳香族複素環化合物を含有する医薬 | |
| JP2007519695A5 (enExample) | ||
| CN110357789B (zh) | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 | |
| MX2011007991A (es) | Derivados de tiadiazoles y oxadiazoles, su preparacion y su uso en terapeutica. | |
| WO2002002542A1 (fr) | Compose annulaire a cinq chainons | |
| WO2005026127A1 (ja) | プラスミノゲンアクチベータインヒビター－１阻害剤 | |
| KR20040093488A (ko) | 화합물 | |
| CN102971291A (zh) | 新型酰胺衍生物及其作为药物的用途 | |
| JP2005517643A5 (enExample) | ||
| JP2010529985A (ja) | 抗真菌活性を有するトリアゾール誘導体、その製造方法、及びこれを含む医薬組成物 | |
| JP4897484B2 (ja) | Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物 |